The network meta‐analysis revealed a clear hierarchy of HCC prevention efficacy across antidiabetic drug classes, with GLP‐1RAs ranking highest (SUCRA 0.89), followed by SGLT‐2 inhibitors and DPP‐4 inhibitors. This evidence concerns the gene SLC5A2 and hepatocellular carcinoma.